LARVOL announced the addition of Mark Lagunowich to their Executive Team. As Vice President, Global Sales, Lagunowich brings over 30 years of experience in the life science industry.
SAN FRANCISCO, CA – February 18, 2021 – (BUSINESS WIRE) –LARVOL, leading provider of intelligence and data solutions to pharma and life science teams, today welcomes Mark Lagunowich as Vice President, Global Sales.
“We are thrilled to welcome Mark to the team at LARVOL,” said founder and CEO Bruno Larvol. “I have been so impressed by Mark’s skills as a sales executive, and this is the perfect time for us to bring on someone of his caliber.”
Lagunowich brings over 30 years of experience in the life science industry to his role at LARVOL. Most recently, he led the Americas Life Science Sales Team for Clarivate Analytics. Prior to that, he spent 8 years as Global VP of Sales at Sparta Systems, and has sold a wide variety of business solutions to pharmaceutical, medical device, and clinical research (CRO) companies.
“I am excited to join Bruno and an incredibly impressive team at LARVOL,” said Lagunowich. “At a time when researchers and pharma companies need to make critical decisions faster than ever, LARVOL solutions are uniquely positioned to provide our customers with critical data using combination of cutting-edge AI and expert curation. LARVOL is strong, fast, and on a mission. I am thrilled to be here.”
Lagunowich rounds out several important new hires for LARVOL including HR and Marketing leadership roles as the company prepares to launch additional oncology-focused solutions this year. VIEW, the first social listening platform aimed at capturing the conversations of oncology opinion leaders on Twitter, will launch at ScaleUp 360 in April. CLIN, a complete database of immuno-oncology clinical trial data will also launch this spring.
LARVOL provides SaaS solutions to support the data and intelligence needs of the pharmaceutical and biotech industry. Their products include competitive intelligence, KOL monitoring, and social listening tools along with predictive cancer biomarker and clinical trial databases. LARVOL curates data using a proven combination of broad therapeutic-area expertise and proprietary natural language processing technology to keep their customers at the forefront of the industry. The 100% remote LARVOL team includes MDs, PhDs, and industry professionals who curate data from over 25,000 sources and distill the most relevant information into concise reports that provide real-time insights and time-saving analysis. For more information, visit LARVOL.com.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network